None listed
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients with Parkinson disease (1) Adult patients aged =19 years (2) Diagnosis of idiopathic PD based on UK Parkinson’s Diseases Society Brain Bank criteria (3) Hoehn and Yahr Scale stage 1–4 (4) Provide voluntary written informed consent to participate in this clinical study
Exclusion criteria
Exclusion criteria: Patient with Parkinson's disease (1) Parkinson-plus syndromes (i.e., multisystem atrophy, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies) (2) History of neuropsychiatric disorder unrelated to PD (3) Moderate or higher cognitive impairment that will interfere with the evaluation (4) History of drug or alcohol abuse (5) History of acute severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage), heart disease (myocardial infarction, heart failure, etc.), or malignant tumor within 6 months before screening, and receiving active treatment (6) Inappropriate for enrollment due to other reasons as determined by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pattern identification questionnaire ;Measurement of pulse and tongue;Unified Parkinson’s Disease Rating Scale (UPDRS) II, III;Gait analysis;Euro-Quality of Life-5 Dimension ;Hoehn & Yahr | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis of changes in blood a-synuclein and cytokines (TNF-a, IFN-?, IL-1 ß, IL-8, etc.);Analysis of microbial diversity and dominant microbial community and diversity | — |
Countries
Korea, Republic of
Contacts
Korea Institute of Oriental Medicine